Thieme E-Books & E-Journals -
Back
CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(01): 15-20
DOI: 10.4103/wjnm.WJNM_20_19
Original Article

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

Majid Assadi
Department of Molecular Imaging and Radionuclide Therapy (MIRT), The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr
,
Samira Rezaei
Department of Molecular Imaging and Radionuclide Therapy (MIRT), The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr
,
Esmail Jafari
Department of Molecular Imaging and Radionuclide Therapy (MIRT), The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr
,
Seyed Javad Rekabpour
1   Department of Oncology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr
,
Mohammad Ravanbod
1   Department of Oncology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr
,
Farshad Zohrabi
2   Department of Urology, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr
,
AbdulLatif Amini
3   Department of Cardiology, Bushehr Heart Medical Center, Bushehr University of Medical Sciences, Bushehr
,
Saeid Keshmiri
4   Department of Anesthesiology (Division of Pain Management), Bushehr Heart Medical Center, Bushehr University of Medical Sciences, Bushehr
,
Habibollah Dadgar
5   Cancer Research Center, RAZAVI Hospital, Imam Reza International University, Mashhad, Iran
,
Hojjat Ahmadzadehfar
6   Department of Nuclear Medicine, University Hospital Bonn, Sigmund-Freud-Str. 25, 53127 Bonn, Germany
› Author Affiliations